Detalles de la búsqueda
1.
Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel.
N Engl J Med
; 385(25): e90, 2021 12 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34551224
2.
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
N Engl J Med
; 385(15): 1355-1371, 2021 10 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34496194
3.
Changes in the Incidence of Invasive Bacterial Disease During the COVID-19 Pandemic in the United States, 2014-2020.
J Infect Dis
; 227(7): 907-916, 2023 04 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36723871
4.
Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data.
Lancet
; 399(10320): 152-160, 2022 01 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34741818
5.
Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March-April 2021.
Clin Infect Dis
; 75(Suppl 2): S155-S158, 2022 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35758873
6.
Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Among Incarcerated People in California State Prisons: Retrospective Cohort Study.
Clin Infect Dis
; 75(1): e838-e845, 2022 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35083482
7.
Identifying and Alleviating Bias Due to Differential Depletion of Susceptible People in Postmarketing Evaluations of COVID-19 Vaccines.
Am J Epidemiol
; 191(5): 800-811, 2022 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35081612
8.
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
MMWR Morb Mortal Wkly Rep
; 71(48): 1526-1530, 2022 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36454688
9.
Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(9): 352-358, 2022 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35239634
10.
Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(7): 255-263, 2022 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35176007
11.
Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022.
MMWR Morb Mortal Wkly Rep
; 71(13): 495-502, 2022 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35358170
12.
Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
MMWR Morb Mortal Wkly Rep
; 71(4): 139-145, 2022 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-35085224
13.
Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.
JAMA
; 327(22): 2210-2219, 2022 06 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35560036
14.
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
JAMA
; 327(7): 639-651, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35060999
15.
Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance.
JAMA
; 327(11): 1032-1041, 2022 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35157002
16.
Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged ≥16 Years in the United States, February-May 2021.
J Infect Dis
; 224(10): 1694-1698, 2021 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-34498052
17.
Intrapartum Antibiotic Exposure and Body Mass Index in Children.
Clin Infect Dis
; 73(4): e938-e946, 2021 08 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33493270
18.
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
MMWR Morb Mortal Wkly Rep
; 70(34): 1163-1166, 2021 Aug 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34437519
19.
Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks - Connecticut, December 2020-February 2021.
MMWR Morb Mortal Wkly Rep
; 70(11): 396-401, 2021 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-33735160
20.
Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalization - Five Veterans Affairs Medical Centers, United States, February 1-August 6, 2021.
MMWR Morb Mortal Wkly Rep
; 70(37): 1294-1299, 2021 Sep 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34529636